Omeros Corporation (NASDAQ: OMER) initiated its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome (aHUS) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE